Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

40.0%

2 terminated/withdrawn out of 5 trials

Success Rate

33.3%

-53.2% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed trials have results

Key Signals

2 recruiting1 with results

Enrollment Performance

Analytics

Phase 2
3(60.0%)
N/A
2(40.0%)
5Total
Phase 2(3)
N/A(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT05917301Not ApplicableRecruiting

Pre-operative Hypofractionated Proton Therapy

Role: collaborator

NCT06376669Phase 2Recruiting

Stereotactic Body Proton Therapy for Treatment of Primary Renal Cell Carcinoma

Role: collaborator

NCT03043794Phase 2Terminated

Study of Stereotactic Radiotherapy for Breast Cancer

Role: collaborator

NCT05302570Phase 2Withdrawn

Neoadjuvant Short-course Hypofractionated PBT for Non-metastatic RPS

Role: collaborator

NCT03487601Not ApplicableCompleted

Transcranial Direct Current Stimulation (tDCS) to Improve Fatigue and Cognitive Function

Role: collaborator

All 5 trials loaded